Melissa Fajardo
Nephrology · New York, NYNPI 1174955579
Payments from drug & device makers
Across 90 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$600
- Novo Nordisk$274
- Amgen$216
- ANI Pharmaceuticals, Inc.$114
- Bayer$110
- Novartis$103
- plus $712 from 15 others
What the payments were for
- Food & beverage$2,11199%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $600 |
| Novo Nordisk | 14 | $274 |
| Amgen(2 entities) | 10 | $216 |
| ANI Pharmaceuticals, Inc. | 4 | $114 |
| Bayer | 4 | $110 |
| Novartis | 4 | $103 |
| Boehringer Ingelheim | 4 | $101 |
| Lilly USA, LLC | 4 | $99 |
| Exact Sciences | 3 | $83 |
| Scpharmaceuticals Inc. | 1 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| GSK | 3 | $53 |
| Madrigal Pharmaceuticals | 2 | $48 |
| Travere Therapeutics, Inc. | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 1 | $33 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Dexcom, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| AbbVie | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
How this compares
$2,129 in reported general payments places this provider in the 65th percentile of 935 nephrology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 172 | $225,105 |
| FarxigaDapagliflozin Propanediol | 164 | $191,446 |
| TrulicityDulaglutide | 72 | $113,652 |
| OzempicSemaglutide | 76 | $94,152 |
| JanuviaSitagliptin Phosphate | 59 | $77,661 |
| JanumetSitagliptin Phos/Metformin Hcl | 52 | $55,960 |
| EliquisApixaban | 48 | $49,424 |
| LokelmaSodium Zirconium Cyclosilicate | 53 | $42,130 |
| LinzessLinaclotide | 51 | $42,077 |
| VascepaIcosapent Ethyl | 52 | $30,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $28,745 |
| EntrestoSacubitril/Valsartan | 21 | $26,011 |
| XareltoRivaroxaban | 23 | $24,436 |
| Diclofenac Sodium ErDiclofenac Sodium | 283 | $22,034 |
| TradjentaLinagliptin | 13 | $17,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Brilinta | $600 | $244,574228 claims |
| Boehringer IngelheimJardiance, Tradjenta | $101 | $242,229185 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $99 | $126,65985 claims |
| Novo NordiskOzempic | $274 | $94,15276 claims |
| PfizerEliquis | $20 | $49,42448 claims |
| AbbVieLinzess | $19 | $42,07751 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $53 | $38,16650 claims |
| NovartisEntresto | $103 | $26,01121 claims |
| BayerKerendia | $110 | $13,47512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 935 nephrology providers in New York.
Other nephrology in New York
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Kirk CampbellNew York$1.1M
- Jai RadhakrishnanNew York$995K
- Girish NadkarniNew York$978K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.